目的:探讨慢性心力衰竭( chronic heart failure，CHF) 病人给予新活素( 冻干重组人脑利钠肽) 治疗对
心功能、高敏C 反应蛋白及血浆NT－proBNP 的影响，并评价其临床应用价值及安全性。方法:选取CHF 病人61
例，随机分为2 组，均接受常规治疗，其中治疗组31 例，给予新活素治疗; 对照组30 例，给予硝酸甘油治疗。观
察两组治疗前后生命体征、呼吸困难程度、C 反应蛋白、射血分数及血浆NT－proBNP 生化指标的变化。结果: 治
疗组总有率高于对照组，射血分数、C 反应蛋白、血浆NT－proBNP 均好于对照组( P＜0． 05) ; LVDD 均无明显变
化，无显著性差异( P＞0． 05) 。结论:新活素可减轻CHF 病人呼吸困难、改善全身状况、提高射血分数、降低血浆
NT－proBNP，并具有良好的安全性。

Objective: To evaluate the efficacy and safety of B－type natriuretic peptide in the treatment
of chronic heart failure( CHF) through objective values of NT－proBNP、C－reaction protein on
plasma． Methods: Randomized，open，control clinical trial was conducted in 61 patients with CHF． 31
of the patients were treated with B－type natriuretic peptide in the trial group，and 30 were treated with
nitroglycerin n the control group． Vital signs，dyspnea，eject fraction( EF) ，NT－proBNP and C－reaction
protein in blood biochemical index before and after drug administration were observed． Results: There
were significant diferences in the increase of the EF， in the decrease of NT－proBNP and C－reaction
protein between the trial group and control group，but no significant diferences were found in LVDD．
Side effects were found in 2 patients of the trial group and 5 patients of the control group． Conclusion:
Levosimendan is effective in treating CHF and it can relieve dyspnea， improve the general condition， in-
crease EF，decrease NT－proBNP and C－reaction protein．

R541． 7

 收稿日期: 2013－04－11; 修回日期: 2013－06－27
基金项目: 国家自然科学基金( 81260269)
作者简介: 皇甫卫忠( 1975－) ，男，内蒙古医科大学附属医院老年病科副主任医师，医学硕士。
通讯作者: 席建军，主任医师，E－mail: huangfufuyuan@163． com 内蒙古医科大学附属医院， 010050